SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 22.79 |
| Enterprise Value ($M) | 13.27 |
| Book Value ($M) | 8.95 |
| Book Value / Share | 2.45 |
| Price / Book | 2.55 |
| NCAV ($M) | 8.92 |
| NCAV / Share | 2.44 |
| Price / NCAV | 2.55 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.07 |
| Return on Assets (ROA) | -0.31 |
| Return on Equity (ROE) | -0.50 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.68 |
| Current Ratio | 10.68 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 9.92 |
| Assets | 9.94 |
| Liabilities | 1.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 7.81 |
| Operating Income | -7.14 |
| Net Income | -9.56 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -10.72 |
| Cash from Investing | -0.40 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 3,207 | 20,477 | 15.66 | |
| 154 | 5,389 | 2.86 | |
| 1,082 | 12,297 | 8.80 | |
| 1,739 | 10,411 | 16.70 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PRTG – Portage Biotech Inc. | PTIX – Protagenic Therapeutics, Inc. |
| PTPI – Petros Pharmaceuticals, Inc. | QLGN – Qualigen Therapeutics, Inc. |
| QTTB – Q32 Bio Inc. |